Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Ugeskr Laeger ; 171(7): 534, 2009 Feb 09.
Artículo en Danés | MEDLINE | ID: mdl-19210941

RESUMEN

Malignant infantile osteopetrosis (MIOP) is a hereditary bone disorder caused by osteoclastic dysfunction. Within the first year of life affected children present with recurrent infections, vision impairment, failure to thrive, bone marrow failure, and at later stages neurological deficits and ultimately death. Bone marrow transplant (BMT) is the only curative treatment. We present a patient with MIOP, who showed the first symptoms at three weeks of age, and the disease was diagnosed at 11 months of age. The boy had a successful BMT after which the delayed psychomotor development improved.


Asunto(s)
Osteopetrosis/complicaciones , Trastornos Psicomotores/etiología , Trasplante de Médula Ósea , Diagnóstico Diferencial , Humanos , Lactante , Recién Nacido , Masculino , Osteopetrosis/diagnóstico , Osteopetrosis/terapia , Trastornos Psicomotores/diagnóstico , Resultado del Tratamiento
2.
Diabetes ; 51(4): 1240-6, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11916951

RESUMEN

In this study, a second case of hyperinsulinemic hypoglycemia due to activation of glucokinase is reported. The 14-year-old proband had a history of neonatal hypoglycemia, treated with diazoxide. He was admitted with coma and convulsions due to nonketotic hypoglycemia. His BMI was 34 kg/m(2), and his fasting blood glucose ranged from 2.1 to 2.7 mmol/l, associated with inappropriately high serum levels of insulin, C-peptide, and proinsulin. An oral glucose tolerance test (OGTT) showed exaggerated responses of these peptides followed by profound hypoglycemia. Treatment with diazoxide and chlorothiazide was effective. His mother never had clinical hypoglycemic symptoms, even though her fasting blood glucose ranged from 2.9 to 3.5 mmol/l. Increases in serum insulin, C-peptide, and proinsulin in response to an OGTT suggested a lower threshold for glucose-stimulated insulin release (GSIR). Screening for mutations in candidate genes revealed a heterozygous glucokinase mutation in exon 10, substituting valine for alanine at codon 456 (A456V) in the proband and his mother. The purified recombinant glutathionyl S-transferase fusion protein of the A456V glucokinase revealed a decreased glucose S(0.5) (the concentration of glucose needed to achieve the half-maximal rate of phosphorylation) from 8.04 (wild-type) to 2.53 mmol/l. The mutant's Hill coefficient was decreased, and its maximal specific activity k(cat) was increased. Mathematical modeling predicted a markedly lowered GSIR threshold of 1.5 mmol/l. The theoretical and practical implications are manifold and significant.


Asunto(s)
Diabetes Mellitus/genética , Glucoquinasa/genética , Glucosa/metabolismo , Mutación Missense , Adolescente , Regulación Alostérica , Diabetes Mellitus/tratamiento farmacológico , Diabetes Mellitus/metabolismo , Diazóxido/uso terapéutico , Activación Enzimática , Glutatión Transferasa/genética , Homeostasis , Humanos , Recién Nacido , Recién Nacido Pequeño para la Edad Gestacional , Insulina/sangre , Insulina/metabolismo , Secreción de Insulina , Cinética , Masculino , Fosforilación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA